tiprankstipranks
Blurbs

Analysts’ Top Healthcare Picks: Molecular Templates (MTEM), Albireo Pharma (ALBO)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Molecular Templates (MTEMResearch Report), Albireo Pharma (ALBOResearch Report) and Pfizer (PFEResearch Report) with bullish sentiments.

Molecular Templates (MTEM)

In a report released yesterday, Stephen Willey from Stifel Nicolaus maintained a Buy rating on Molecular Templates, with a price target of $11.00. The company’s shares closed last Wednesday at $3.38, close to its 52-week low of $2.22.

According to TipRanks.com, Willey is a 5-star analyst with an average return of 17.7% and a 47.2% success rate. Willey covers the Healthcare sector, focusing on stocks such as Inovio Pharmaceuticals, AbCellera Biologics, and SQZ Biotechnologies.

Currently, the analyst consensus on Molecular Templates is a Moderate Buy with an average price target of $4.50, a 38.5% upside from current levels. In a report released yesterday, Barclays also maintained a Buy rating on the stock with a $4.50 price target.

See Insiders’ Hot Stocks on TipRanks >>

Albireo Pharma (ALBO)

In a report issued on March 29, Brian Skorney from Robert W. Baird maintained a Buy rating on Albireo Pharma, with a price target of $72.00. The company’s shares closed last Wednesday at $30.83.

According to TipRanks.com, Skorney has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -4.4% and a 43.5% success rate. Skorney covers the Healthcare sector, focusing on stocks such as Eiger Biopharmaceuticals, Vertex Pharmaceuticals, and Enanta Pharmaceuticals.

Albireo Pharma has an analyst consensus of Strong Buy, with a price target consensus of $74.75, a 136.0% upside from current levels. In a report issued on March 28, Wedbush also initiated coverage with a Buy rating on the stock with a $75.00 price target.

Pfizer (PFE)

Evercore ISI analyst Umer Raffat maintained a Buy rating on Pfizer yesterday. The company’s shares closed last Wednesday at $52.44.

According to TipRanks.com, Raffat is ranked 0 out of 5 stars with an average return of -6.4% and a 44.4% success rate. Raffat covers the Healthcare sector, focusing on stocks such as Amylyx Pharmaceuticals Inc, Phathom Pharmaceuticals, and Teva Pharmaceutical.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Pfizer with a $61.21 average price target, which is a 15.1% upside from current levels. In a report issued on March 22, Wells Fargo also maintained a Buy rating on the stock with a $60.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on MTEM:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed